To include your compound in the COVID-19 Resource Center, submit it here.

Roclatan netarsudil/latanoprost: Phase III started

Aerie began the double-blind, U.S. Phase III Mercury 2 trial to compare once-daily netarsudil 0.02%/latanoprost

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE